Researchers Identified Breast Cancer Response Pathways
A study analyzed how immune-related pathways influence patient response to a specific triple-drug therapy.
Updated on Sept. 19, 2026 in Cancer
Live Poll
Do you believe new drug combination research effectively improves long-term cancer patient outcomes?
Scientists evaluated tumor biopsies from 19 patients with advanced HER2-negative breast cancer during a Phase Ib clinical trial. The study identified specific immune and interferon pathways that correlate with positive responses to a combination therapy of entinostat, nivolumab, and ipilimumab.
Why it matters
Understanding these immune-related pathways is essential for improving the efficacy of immunotherapy combinations in difficult-to-treat cancer cases. These findings provide a biological roadmap for identifying patients who are most likely to benefit from this specific treatment strategy.
Researchers utilized RNA-seq and T-cell receptor data from 37 tumor biopsies across 19 patients. The clinical investigation analyzed patient responses after 8 weeks of therapy versus baseline levels.
The players
NCT02453620
This is the clinical trial identifier for the Phase Ib study investigating the combination of entinostat, nivolumab, and ipilimumab.
The details
The team employed bulk RNA-seq and PAM50 analysis to categorize tumor subtypes and investigate how immune-related pathways shift during treatment. Findings revealed that patients who responded to therapy showed higher baseline T-cell receptor diversity and enrichment of interferon signaling markers.
Timeline
Week 8 marks the collection point for post-triplet therapy biopsies.
The Big Picture
This study aligns with the NCI's Cancer Moonshot initiative by deepening the molecular understanding of immunotherapy resistance in breast cancer. This research follows a pattern set by the initiative to prioritize precision molecular profiling in clinical immunotherapy trials.
These findings could eventually lead to better screening tools that help oncologists predict if a patient will respond to immunotherapy before treatment begins. Patients currently undergoing clinical trials should consult their care teams about how these molecular markers apply to their personalized treatment plans.
The takeaway
The study underscores the importance of baseline T-cell diversity as a potential biomarker for immunotherapy success. Future cancer treatments may rely more heavily on these genetic signatures to personalize therapeutic combinations for each patient.
Further reading
For more on evolving research, visit our Cancer section.
More information
View the peer-reviewed research article for complete methodological details.
Live Poll
Do you believe new drug combination research effectively improves long-term cancer patient outcomes?
